Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: UCB.BRU
Batch: 6
Published: July 5, 2026
AI Advisors: 12

Historical AI Consensus Investment Thesis

UCB (UCB) Stock Forecast and AI Rating

Deep analysis published Jul 05 2026Original pricing snapshot Jul 03 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Frozen consensus rating from this immutable batch publication.

2027

1-Year

BUY

€288

+11.0%+11.6% incl. dividends

2031

5-Year

BUY

€425

+63.7%+67.8% incl. dividends

Published batch insight

Unlevered Immunology Leader Set to Outperform Amid Global Stagflation and Rate Pressures

High consensus exists regarding the asset's transition into a self-funding immunology powerhouse, insulated from macroeconomic shocks by its unlevered balance sheet. While US pricing regulations and legacy patent cliffs present structural frictions, the rapid global scaling of its blockbuster immunology portfolio remains the primary driver of long-term value.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.

Computed on these frontier AI models

Gemini

Full published thesis

Executive Summary

If you invested $10,000 in UCB at publication: $16,748 in five years versus $14,069 for S&P 500 benchmark.

UCBS&P 500 benchmark

* Return is calculated incl. 0.5% net dividend yield for UCB.

Figure: Five-year consensus value path for UCB compared with S&P 500 benchmark. The shaded band shows dispersion across advisor forecasts.

The asset is undergoing a structural transition from a legacy neurology-focused firm into a high-margin, self-funding immunology powerhouse. Backed by an exceptionally low debt-to-equity ratio of 0.21 and robust free cash flow generation, the company is highly insulated from the current restrictive monetary regime and European stagflation. While legacy patent cliffs and US pricing regulations act as persistent frictions, the rapid global scaling of its blockbuster immunology portfolio and rare disease franchise will drive sustained intrinsic value compounding over the five-year horizon.

Key insights

Best-in-class clinical efficacy of the core immunology asset drives rapid global market share capture and establishes a widening economic moat.
Pristine balance sheet with minimal leverage completely insulates the capital structure from refinancing risks and elevated borrowing costs.
Low physical capital intensity combined with high cash conversion yields an elite free cash flow profile that funds organic pipeline expansion.
Strategic onshoring of manufacturing networks establishes a robust geopolitical moat against supply chain disruptions and regulatory decoupling pressures.
Near-term margin compression from recent clinical-stage acquisitions represents a temporary capital allocation drag rather than structural operational decay.
Regulatory pricing pressures in the US market limit terminal pricing power but fail to derail the volume-driven growth trajectory.
Integration of advanced computational biology and AI-driven drug discovery platforms structurally accelerates pipeline velocity and reduces long-term R&D costs.

Deep Dive

The prevailing market consensus views the asset through a conventional, single-product lens, focusing heavily on the commercial launch of its flagship immunology drug to offset patent cliffs for legacy epilepsy treatments. Sell-side analysts and media outlets largely treat the company as a standard, defensive European pharmaceutical play. They anchor their valuations to near-term prescription volumes and competitive battles in the immunology market. Furthermore, the crowd remains skeptical of recent clinical-stage acquisitions, viewing them as expensive attempts to buy growth that drag on near-term margins, while overlooking the structural transformation of the company's underlying cash-flow generation capabilities.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The core information gap lies in the market's failure to recognize the asset's profound balance sheet resilience and structural cash-flow dynamics within a hostile macroeconomic environment. While the crowd values the company as a typical product-cycle biopharma vulnerable to multiple compression, it operates as an unlevered, self-funding compounding engine with a debt-to-equity ratio of just 0.21 and expanding free cash flow margins. Furthermore, the market systematically misprices the geopolitical premium of the company's localized European and US manufacturing networks. In a regime dominated by supply chain decoupling and the BIOSECURE Act, this localized infrastructure transitions from an operational detail into a major competitive advantage, shielding the firm from disruptions that threaten China-dependent peers.

Repricing catalyst

The convergence of the crowd narrative toward the consensus will be triggered by successive quarterly earnings reports demonstrating sustained free cash flow expansion and gross margin resilience despite global stagflation. This operational strength will be highlighted by the flagship immunology drug consistently beating market share estimates. Additionally, the successful integration of recent acquisitions and the validation of onshored manufacturing facilities will dismantle the margin-decay thesis. As trailing valuation multiples compress mechanically against soaring earnings, generalist macro allocators will be forced to rotate capital into the asset as a high-yield, zero-leverage safe haven.

Published consensus context

Macro regime alignment

The current macroeconomic backdrop of war-driven stagflation, persistent inflation, and restrictive monetary policy serves as a powerful relative tailwind. While high interest rates and tightening credit conditions severely penalize leveraged, capital-intensive equities, the asset's minimal debt and self-funding cash generation render it virtually immune to refinancing risks. Furthermore, demand for its severe-disease therapeutics is highly inelastic, protecting operating margins from cyclical economic contractions and energy shocks. The strong US dollar regime also acts as an organic margin expander, as the company realizes high-margin US revenues against a partially Euro-denominated cost base.

Published consensus context

Advisor disagreement

The primary disagreements across the reports center on the valuation multiple and near-term margin trajectories. Some perspectives argue that the current multiple of 29x P/E is fully justified by explosive top-line growth, while others caution that it leaves zero margin of safety, predicting a prolonged sideways valuation compression. Disagreements also stem from differing assumptions regarding the impact of recent acquisitions; some view the R&D spend as a prudent, self-funded capital allocation strategy to bridge a clinical catalyst desert, while others penalize it as structural margin decay.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Bimzelx Global Commercial Scaling: The rapid global commercialization of the flagship immunology drug Bimzelx serves as the primary growth engine. Its clinically superior dual IL-17A/F inhibition mechanism drives rapid market share capture in psoriasis and hidradenitis suppurativa, beating entrenched competitors. This highly inelastic, high-margin revenue stream is scaling across fifty countries, providing immense operating leverage and structurally elevating the company's long-term earnings power independently of broader macroeconomic cycles. Expected impact: +35%.
Fortress Balance Sheet and Cash Flow: Operating with an exceptionally low debt-to-equity ratio of 0.21 and generating robust free cash flow, the company possesses absolute financial sovereignty. This unlevered capital structure completely insulates the firm from restrictive monetary policies and refinancing risks. The massive cash generation allows the company to self-fund its extensive R&D pipeline and strategic acquisitions without relying on expensive external credit markets. Expected impact: +18%.
Rare Disease Franchise Maturation: The successful commercialization of specialized rare disease assets like Rystiggo and Zilbrysq establishes a highly durable, secondary revenue pillar. Targeting severe unmet medical needs with small patient populations grants the company significant pricing power and extended regulatory exclusivity. This franchise diversifies the cash flow base away from pure immunology, securing high-margin recurring revenues that are insulated from economic downturns. Expected impact: +15%.
BIOSECURE Supply Chain Moat: As geopolitical tensions prompt US decoupling from Chinese contract manufacturers under the BIOSECURE Act, the company's localized European and US manufacturing footprint becomes a major strategic asset. This supply chain sovereignty protects the firm from trade disruptions and regulatory penalties, allowing it to capture market share from competitors facing forced, expensive supply chain reorganizations. Expected impact: +10%.

Top frictions and headwinds

US Regulatory Pricing Pressure: The implementation of aggressive US pharmaceutical pricing regulations, such as executive pricing mandates and Medicare negotiation frameworks, acts as a structural drag on net realized prices. While volume growth remains robust, these policy interventions limit the terminal pricing power of blockbuster biologics in the highest-margin global market, compressing peak lifecycle earnings assumptions. Expected impact: -12%.
Legacy Portfolio Patent Cliffs: The ongoing genericization of legacy neurology and immunology assets, such as Vimpat and Cimzia, introduces a persistent revenue drag. As patent protections expire, these high-margin cash flows face rapid erosion from generics and biosimilars. This forces the newer product cycle to grow at an accelerated pace simply to offset the baseline decay of legacy assets. Expected impact: -10%.
M&A-Driven R&D and SG&A Bloat: Recent clinical-stage acquisitions and the intense commercial spend required to defend market share against deeply capitalized incumbents inflate operating expenses. This elevated investment intensity temporarily compresses EBITDA margins and drags on near-term return on invested capital, creating an optical deterioration in profitability that near-term models and algorithmic traders may penalize. Expected impact: -8%.
Stagflationary Input Cost Inflation: European stagflation and global logistics disruptions, including maritime chokepoint blockades, exert upward pressure on manufacturing and distribution costs. Complex biologics require specialized cold-chain logistics and packaging materials, making the supply chain vulnerable to energy and chemical price spikes, which temporarily degrade gross margins until localized production is fully scaled. Expected impact: -5%.

Tail risks

Post-Marketing Safety Signal Emergence: Real-world commercial data could reveal an unexpected, severe post-marketing safety signal associated with a core growth driver. This would lead to immediate regulatory black-box warnings or restricted prescribing protocols, collapsing the drug's commercial trajectory, destroying the primary growth thesis, and triggering a severe valuation downgrade. Probability: +15%. Expected impact: -35%.
Drastic US Price Controls: Populist political momentum in the US could result in the implementation of hard international reference pricing or sweeping price controls on biologics. Because the US market drives the vast majority of the company's profitability, this structural shift would permanently compress gross margins and severely restrict pipeline reinvestment capacity. Probability: +25%. Expected impact: -25%.

Tail opportunities

Accelerated Broad Label Expansion: Regulatory agencies could grant earlier-than-expected approvals for the flagship immunology drug across a wider spectrum of autoimmune indications. This would dramatically expand the total addressable market, resetting peak sales estimates upward by billions of dollars and forcing a structural upward re-rating of the equity multiple. Probability: +40%. Expected impact: +20%.
Predatory Distressed Biotech Acquisitions: Leveraging its fortress balance sheet and massive free cash flow, the company could execute highly accretive, counter-cyclical acquisitions of distressed clinical-stage biotech firms. In a high-rate environment where smaller peers face capital starvation, acquiring late-stage assets at firesale valuations would rapidly replenish the long-term pipeline without diluting equity. Probability: +30%. Expected impact: +15%.

Company Financial Analysis

UCB Earnings and Financials Analysis by AI

Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The company's financial performance is exceptionally strong, marked by a massive 25.8% jump in revenue and a doubling of its free cash flow in 2025. This explosive growth shows that the company has successfully moved past the threat of older drugs losing their patents and is now reaping huge rewards from its new immunology treatments. Analysts agree that the company is generating high-quality, real cash flows rather than relying on accounting tricks. However, there is some disagreement about the future profit outlook. Some experts warn that recent expensive company purchases and the high costs of competing in the US market will temporarily squeeze profits over the next few years. Others believe the sheer volume of new drug sales will easily overpower these costs, keeping the company on a highly profitable path. Overall, the financial trend is highly positive and supportive of long-term growth.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	EUR 7.7B	EUR 1.6B	EUR 1.9B
2024	EUR 6.2B	EUR 1.1B	EUR 920M
2023	EUR 5.3B	EUR 343M	EUR 445M
2022	EUR 5.5B	EUR 418M	EUR 748M
2021	EUR 5.8B	EUR 1.1B	EUR 1.1B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	17.3x	TTM	Native	EUR / EUR
2024	26.5x	TTM	Native	EUR / EUR
2023	--	TTM	Unavailable	EUR / EUR
2022	33.8x	Annual	Native	EUR / EUR
2021	18.4x	Annual	Native	EUR / EUR

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

The company enjoys outstanding profitability, with gross margins holding steady at a remarkable 71%. This means the company has immense pricing power and its products are highly profitable to make. However, there is a clear clash of opinions regarding the future direction of operating margins. Some analysts are highly optimistic, believing that as sales of its blockbuster skin drug scale up globally, profit margins will naturally expand toward the mid-20% range. Conversely, more cautious observers warn that the company faces a temporary margin squeeze. They point to the high costs of integrating recent acquisitions and the intense marketing battles required to fight off large competitors in the US. While the current stock price reflects a premium for this profitability, the general consensus is that the company's margins are highly resilient and well-protected against inflation, making it a very attractive defensive investment.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	EUR 1.2B	15.1%	20.1%
2024	EUR 1.3B	21.5%	17.3%
2023	EUR 604M	11.5%	6.5%
2022	EUR 400M	7.3%	7.6%
2021	EUR 1.1B	19.9%	18.3%

Balance sheet and leverage

AI Review

The company's balance sheet is described as an absolute financial fortress, offering incredible safety for investors. With an extremely low debt-to-equity ratio of 0.21 and virtually no reliance on external borrowing, the company is completely safe from rising interest rates and tight credit markets. Analysts are in complete agreement that this financial health is a massive competitive advantage. It allows the company to easily pay off its debts early and fund its multi-billion-dollar US factory expansion entirely with its own cash. There is virtually no disagreement on the safety of the balance sheet; it provides strong protection against economic downturns. Furthermore, this financial firepower gives the company the unique ability to buy up struggling, cash-starved competitors at bargain prices, turning a tough economic environment into a major growth opportunity.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	EUR 2.2B	EUR 2.5B	EUR 6M net cash	1.38x
2024	EUR 3B	EUR 1.8B	EUR 1.5B net debt	1.36x
2023	EUR 3B	EUR 969M	EUR 2.2B net debt	1.32x
2022	EUR 2.9B	EUR 1.1B	EUR 2B net debt	1.06x
2021	EUR 2.1B	EUR 1.4B	EUR 860M net debt	1.31x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

The company is managing its spending very wisely. While traditional physical spending on factories and equipment is low at just 3.6% of revenue, the company is investing heavily in research and development (R&D) and strategic acquisitions to secure its future. A major point of consensus is the company's massive five-billion-dollar plan to build manufacturing facilities in the United States. This heavy spending is both an offensive move to support its growing drug sales and a defensive shield to protect its supply chain from global political tensions. While some analysts worry that this heavy capital spending will temporarily reduce the amount of free cash flow available, most agree it is a highly smart, self-funded investment that builds a strong competitive advantage. Opinions differ slightly on how quickly these investments will pay off, but the general agreement is that the company's low-debt model makes this heavy spending safe and highly beneficial.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	EUR 281M	EUR 1.8B
2024	EUR 322M	EUR 1.8B
2023	EUR 316M	EUR 1.6B
2022	EUR 371M	EUR 1.7B
2021	EUR 493M	EUR 1.6B

Immutable published data

Consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	161	+11.6%	Not available	ORIGINAL
5Y	BUY	177	+67.8%	Not available	ORIGINAL

Consensus forecast path

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	October 3, 2026	251.72	267.72	275.07	12
+6M	January 3, 2027	246.68	274.28	288.82	12
+9M	April 3, 2027	249.15	282.08	300.38	12
+1Y	July 3, 2027	239.18	288.15	321.4	12
+15M	October 3, 2027	243.97	292.74	315.52	12
+18M	January 3, 2028	246.4	301.17	331.29	12
+21M	April 3, 2028	253.8	310.11	346.99	12
+2Y	July 3, 2028	258.87	319.04	360.87	12
+27M	October 3, 2028	253.7	325.96	371.7	12
+30M	January 3, 2029	263.84	336.83	390.28	12
+33M	April 3, 2029	271.76	345.9	387.08	12
+3Y	July 3, 2029	269.04	349.97	405.42	12
+39M	October 3, 2029	274.42	360.06	422.69	12
+42M	January 3, 2030	282.65	372.55	439.6	12
+45M	April 3, 2030	277	379.11	447.32	12
+4Y	July 3, 2030	282.54	380.57	456.96	12
+51M	October 3, 2030	291.02	392.26	475.24	12
+54M	January 3, 2031	293.93	404.03	489.5	12
+57M	April 3, 2031	299.81	413.66	489.5	12
+5Y	July 3, 2031	308.8	424.8	504.19	12

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 744.78 on July 2, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	October 2, 2026	714.9888	736.0909	759.6756
+6M	January 2, 2027	657.7897	724.1434	782.4659
+9M	April 2, 2027	592.0107	713.5711	790.2905
+1Y	July 2, 2027	562.4102	723.3821	821.9021
+15M	October 2, 2027	539.9138	716.6125	813.6831
+18M	January 2, 2028	550.7121	738.3442	869.6268
+21M	April 2, 2028	534.1907	746.9119	913.1081
+2Y	July 2, 2028	534.1907	771.9272	967.8946
+27M	October 2, 2028	566.2421	782.7251	938.8578
+30M	January 2, 2029	574.4406	807.3094	995.1893
+33M	April 2, 2029	597.4182	822.722	1,074.8044
+3Y	July 2, 2029	615.3408	846.0985	1,117.7966
+39M	October 2, 2029	624.1488	852.525	1,117.7966
+42M	January 2, 2030	649.1147	882.9093	1,173.6864
+45M	April 2, 2030	668.5882	900.4585	1,232.3707
+4Y	July 2, 2030	681.9599	922.6675	1,281.6656
+51M	October 2, 2030	695.5991	935.9097	1,320.1155
+54M	January 2, 2031	716.4671	952.2951	1,293.7132
+57M	April 2, 2031	730.7964	976.2817	1,345.4617
+5Y	July 2, 2031	738.1044	1,001.9601	1,385.8256

Frozen comparison context

EURUSD.FOREX forecast context

The batch's original direct_listing_to_usd path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 1.14 on July 3, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	October 3, 2026	1.1058	1.1229	1.1628
+6M	January 3, 2027	1.0837	1.1119	1.1744
+9M	April 3, 2027	1.0512	1.1011	1.1979
+1Y	July 3, 2027	1.0302	1.1013	1.2099
+15M	October 3, 2027	1.0095	1.1013	1.2099
+18M	January 3, 2028	0.9894	1.1016	1.2098
+21M	April 3, 2028	0.9894	1.1058	1.2219
+2Y	July 3, 2028	1.0091	1.1079	1.234
+27M	October 3, 2028	0.9891	1.1121	1.2587
+30M	January 3, 2029	0.9792	1.1138	1.2587
+33M	April 3, 2029	0.9694	1.1162	1.2711
+3Y	July 3, 2029	0.9985	1.122	1.271
+39M	October 3, 2029	0.9785	1.1263	1.2837
+42M	January 3, 2030	0.9687	1.1278	1.2837
+45M	April 3, 2030	0.959	1.1296	1.3094
+4Y	July 3, 2030	0.959	1.1291	1.2963
+51M	October 3, 2030	0.9494	1.132	1.3092
+54M	January 3, 2031	0.9494	1.1343	1.3094
+57M	April 3, 2031	0.9399	1.1349	1.3354
+5Y	July 3, 2031	0.9493	1.1376	1.3354

Research Provenance

References & Context

This UCB consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

File size: 90.8K bytes
Words: 12.8K words
Characters: 90.8K characters

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market Context through 2026-05-31

Download Archived Snapshot

Coverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31

File size: 78K bytes
Words: 10.9K words
Characters: 78K characters

This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.

It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.

Top 3 market shifts from 2026 Year-to-Date Global Market Context through 2026-05-31
Top 3 Market Shifts From File	Date	Status
The Iran and Strait of Hormuz conflict shocked energy markets	2026-02-28	STARTED AND ONGOING
U.S. monetary policy entered the Warsh transition	2026-01-30	STARTED AND ACTIVE POLICY TRANSITION
Agentic AI and infrastructure spending kept expanding	2026-01-01	OPEN ENDED

Representative Sources of the Context File

Federal Reserve U.S. Bureau of Labor Statistics U.S. Bureau of Economic Analysis U.S. Treasury U.S. Energy Information Administration Reuters Associated Press BBC News

And more sources from the retained context package.

Fundamental context

Income statement

34 fields

costOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields

Balance sheet

64 fields

accountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields

Cash flow

32 fields

beginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields

annual: 2023-12-31–2025-12-31, 3 periods; quarterly: 2024-06-30–2025-12-31, 3 periods

Currencies cited: EUR, USD (quote EUR; primary reporting EUR; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.